Masecampo, Verlyn D.
HRN: 24-37-59 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/17/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
01/17/2024
01/24/2024
IV
1.5g
Q6
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes